AZN
Neutral signalScored 2026-10-06 Drivers: Congress, fundamentals. Moteurs : Congrès, fondamentaux.
Research, not advice.
À propos
AstraZeneca PLC
- Nom
- AstraZeneca PLC
- Secteur
- Healthcare
- Industrie
- Drug Manufacturers - General
- Bourse
- NYSE
- Capitalisation
- $265.5B
- Employés
- 96,100
- PDG
- Pascal Claude Roland Soriot
- Site web
- https://www.astrazeneca.com
- Marché
- ABBVAMGNBMYJNJLLYMRK
AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris. AstraZeneca engages with primary and specialty care physicians worldwide, facilitating distribution through a robust network of representatives and local offices across the United Kingdom, continental Europe, the Americas, Asia, Africa, and Australasia. The firm actively drives innovation through strategic collaborations, partnering with entities such as Neurimmune AG for the development and commercialization of NI006, BenevolentAI for systemic lupus erythematosus drug discovery, Lunit for AI-powered digital pathology risk assessment in NSCLC, and Absci Corporation for AI-driven oncology target identification. Founded in 1992, the company was initially known as Zeneca Group PLC, subsequently rebranding to AstraZeneca PLC in April 1999, and maintains its headquarters in Cambridge, United Kingdom.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
ACHAT TOTAL: 20 titres (~3249 USD)
- Insiders
- Sharma Mani
- Total bought
-
$3,249
Avg buy (VWAP, 90d window) $160.57 vs last close —
- Total sold
-
—
Avg sell (VWAP, 90d window) —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-08-08
- Last synced
-
2026-10-06 10:56:08
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-08-08 | Sharma Mani | Buy · P | 20 | $160.57 | $3,249 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2025-12-18 | Gilbert Ray Cisneros | Purchase | $1,001 - $15,000 |
| 2025-12-08 | Julia Letlow | Purchase | $1,001 - $15,000 |
| 2025-11-19 | Gilbert Ray Cisneros | Purchase | $1,001 - $15,000 |
| 2025-10-31 | Lisa C. McClain | Sale (Full) | $1,001 - $15,000 |
| 2025-10-30 | Lisa C. McClain | Sale (Full) | $1,001 - $15,000 |
| 2025-10-30 | Lisa C. McClain | Purchase | $1,001 - $15,000 |
| 2025-10-21 | Gilbert Ray Cisneros | Purchase | $1,001 - $15,000 |
| 2025-09-23 | Val Hoyle | Sale (Full) | $1,001 - $15,000 |
| 2025-07-22 | Lisa C. McClain | Purchase | $1,001 - $15,000 |
| 2025-06-17 | Lisa C. McClain | Sale (Partial) | $1,001 - $15,000 |
| 2025-06-09 | Lisa C. McClain | Purchase | $1,001 - $15,000 |
| 2025-04-21 | Bruce Westerman | Sale (Full) | $1,001 - $15,000 |
| 2025-03-03 | Bruce Westerman | Purchase | $1,001 - $15,000 |
| 2024-10-29 | Val Hoyle | Purchase | $1,001 - $15,000 |
| 2023-10-13 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-08-14 | Michael T. McCaul | Sale | $50,001 - $100,000 |
| 2023-08-14 | Michael T. McCaul | Sale | $100,001 - $250,000 |
| 2023-08-11 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-07-31 | Michael T. McCaul | Sale | $15,001 - $50,000 |
| 2023-07-31 | Michael T. McCaul | Sale | $15,001 - $50,000 |
| 2023-07-10 | Daniel Goldman | Sale (Full) | $100,001 - $250,000 |
| 2023-07-06 | Michael T. McCaul | Sale | $15,001 - $50,000 |
| 2023-07-06 | Michael T. McCaul | Sale | $50,001 - $100,000 |
| 2023-05-02 | Michael T. McCaul | Sale | $15,001 - $50,000 |
| 2023-05-02 | Michael T. McCaul | Sale | $15,001 - $50,000 |
| 2023-02-10 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2022-12-16 | Michael T. McCaul | Sale | $1,001 - $15,000 |
| 2022-12-16 | Michael T. McCaul | Sale | $1,001 - $15,000 |
| 2022-05-05 | Michael T. McCaul | Purchase | $50,001 - $100,000 |
| 2022-05-05 | Michael T. McCaul | Purchase | $50,001 - $100,000 |
| 2022-04-28 | Michael T. McCaul | Purchase | $100,001 - $250,000 |
| 2022-04-28 | Michael T. McCaul | Purchase | $100,001 - $250,000 |
| 2021-12-01 | Alan Lowenthal | Sale (Full) | $1,001 - $15,000 |
| 2021-07-21 | Dean Phillips | Exchange | $1,001 - $15,000 |
| 2021-04-09 | Sara Jacobs | Sale (Full) | $15,001 - $50,000 |
| 2021-02-22 | Alan Lowenthal | Purchase | $1,001 - $15,000 |
| 2021-02-22 | Alan Lowenthal | Purchase | $50,001 - $100,000 |
| 2021-02-22 | Alan Lowenthal | Purchase | $15,001 - $50,000 |
| 2020-02-24 | Thomas Suozzi | Sale (Full) | $15,001 - $50,000 |
| 2020-01-15 | John Henry Rutherford | Sale (Full) | $1,001 - $15,000 |
| 2020-01-07 | Thomas Suozzi | Purchase | $15,001 - $50,000 |
| 2019-05-28 | Mikie Sherrill | Sale (Full) | $1,001 - $15,000 |
| 2019-01-14 | Van Taylor | Sale (Full) | $1,001 - $15,000 |
| 2019-01-07 | Van Taylor | Sale (Full) | $1,001 - $15,000 |
| 2017-07-11 | John Henry Rutherford | Purchase | $1,001 - $15,000 |
Signal
Neutral signalScored 2026-10-06 Drivers: Congress, fundamentals. Moteurs : Congrès, fondamentaux.
AstraZeneca combines solid fundamental momentum (strong ROIC trajectory, consistent deleveraging, robust cash flows) with a credible oncology-driven catalyst in its $2B Summit Therapeutics investment and new clinical…
The first sentence of the analysis written for AZN on 2026-10-06 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Neutral signal
Drivers: Congress, fundamentals. Moteurs : Congrès, fondamentaux.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Congress Pulls against a bullish reading. STOCK Act sale disclosures outnumber purchases
- Narrative Supports a bullish reading. Stored narrative reading is in the bullish band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Unavailable or mixed. Current ratio 0.94 · operating margin 23% — readings disagree
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 81.9% | 81.1% | 82.0% | 72.1% | 66.8% | |
| Ebit Margin | 24.0% | 19.2% | 18.5% | 8.6% | 2.7% | |
| Ebitda Margin | 33.8% | 28.6% | 29.3% | 20.5% | 13.7% | |
| Operating Profit Margin | 23.4% | 18.5% | 17.9% | 8.5% | 2.8% | |
| Pretax Profit Margin | 21.1% | 16.1% | 15.1% | 5.6% | -0.7% | |
| Continuous Operations Profit Margin | 17.4% | 13.0% | 13.0% | 7.4% | 0.3% | |
| Net Profit Margin | 17.5% | 13.0% | 13.0% | 7.4% | 0.3% | |
| Bottom Line Profit Margin | 17.5% | 13.0% | 13.0% | 7.4% | 0.3% | |
| Current Ratio | 0.938 | 0.927 | 0.820 | 0.859 | 1.162 | |
| Quick Ratio | 0.724 | 0.737 | 0.643 | 0.681 | 0.764 | |
| Solvency Ratio | 0.245 | 0.192 | 0.176 | 0.144 | 0.064 | |
| Cash Ratio | 0.187 | 0.197 | 0.191 | 0.235 | 0.280 | |
| Price To Earnings Ratio | 26.591 | 28.634 | 34.858 | 64.255 | 1,448.125 | |
| Price To Earnings Growth Ratio | 0.586 | 1.494 | 0.437 | 0.025 | -14.972 | |
| Forward Price To Earnings Growth Ratio | 0.586 | 1.494 | 0.437 | 0.025 | -14.972 | |
| Price To Earnings Diluted Ratio | 26.835 | 28.889 | 34.858 | 64.559 | 1,448.125 | |
| Price To Earnings Diluted Growth Ratio | 0.592 | 1.595 | 0.433 | 0.025 | -14.972 | |
| Price To Book Ratio | 5.590 | 4.940 | 5.300 | 5.693 | 4.183 | |
| Price To Sales Ratio | 4.631 | 3.726 | 4.528 | 4.755 | 4.390 | |
| Price To Free Cash Flow Ratio | 31.375 | 27.698 | 31.590 | 29.138 | 43.655 | |
| Price To Operating Cash Flow Ratio | 18.664 | 16.988 | 20.053 | 21.500 | 27.549 | |
| Debt To Assets Ratio | 0.260 | 0.289 | 0.283 | 0.302 | 0.291 | |
| Debt To Equity Ratio | 0.610 | 0.738 | 0.731 | 0.787 | 0.782 | |
| Debt To Capital Ratio | 0.379 | 0.425 | 0.422 | 0.440 | 0.439 | |
| Long Term Debt To Capital Ratio | 0.337 | 0.394 | 0.364 | 0.383 | 0.417 | |
| Financial Leverage Ratio | 2.344 | 2.551 | 2.583 | 2.605 | 2.683 | |
| Working Capital Turnover Ratio | -29.870 | -14.368 | -9.972 | -1,774.040 | 25.921 | |
| Operating Cash Flow Ratio | 0.476 | 0.426 | 0.339 | 0.373 | 0.264 | |
| Operating Cash Flow Sales Ratio | 0.248 | 0.219 | 0.226 | 0.221 | 0.159 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.595 | 0.613 | 0.635 | 0.738 | 0.631 | |
| Debt Service Coverage Ratio | 3.620 | 3.592 | 1.858 | 1.507 | 1.932 | |
| Interest Coverage Ratio | 8.113 | 5.947 | 5.156 | 2.825 | 0.828 | |
| Short Term Operating Cash Flow Coverage Ratio | 4.576 | 5.501 | 2.017 | 1.877 | 3.805 | |
| Operating Cash Flow Coverage Ratio | 0.491 | 0.394 | 0.361 | 0.337 | 0.194 | |
| Capital Expenditure Coverage Ratio | 2.468 | 2.586 | 2.738 | 3.815 | 2.710 | |
| Dividend Paid And Capex Coverage Ratio | 1.340 | 1.287 | 1.253 | 1.414 | 0.985 | |
| Dividend Payout Ratio | 0.485 | 0.658 | 0.752 | 1.327 | 34.429 | |
| Enterprise Value Multiple | 14.928 | 14.647 | 17.153 | 25.740 | 36.893 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 81.9% | ▲0.8% | ▲5.1% |
| Ebit Margin | 24.0% | ▲4.8% | ▲9.4% |
| Ebitda Margin | 33.8% | ▲5.2% | ▲8.6% |
| Operating Profit Margin | 23.4% | ▲4.9% | ▲9.2% |
| Pretax Profit Margin | 21.1% | ▲5.0% | ▲9.7% |
| Continuous Operations Profit Margin | 17.4% | ▲4.4% | ▲7.2% |
| Net Profit Margin | 17.5% | ▲4.5% | ▲7.2% |
| Bottom Line Profit Margin | 17.5% | ▲4.5% | ▲7.2% |
| Current Ratio | 0.938 | ▲0.011 | ▼-0.003 |
| Quick Ratio | 0.724 | ▼-0.013 | ▲0.014 |
| Solvency Ratio | 0.245 | ▲0.053 | ▲0.081 |
| Cash Ratio | 0.186 | ▼-0.010 | ▼-0.031 |
| Price To Earnings Ratio | 26.591 | ▼-2.043 | ▼-293.902 |
| Price To Earnings Growth Ratio | 0.586 | ▼-0.908 | ▲3.072 |
| Forward Price To Earnings Growth Ratio | 0.586 | ▼-0.908 | ▲3.072 |
| Price To Earnings Diluted Ratio | 26.835 | ▼-2.054 | ▼-293.818 |
| Price To Earnings Diluted Growth Ratio | 0.592 | ▼-1.003 | ▲3.057 |
| Price To Book Ratio | 5.590 | ▲0.649 | ▲0.448 |
| Price To Sales Ratio | 4.631 | ▲0.905 | ▲0.225 |
| Price To Free Cash Flow Ratio | 31.375 | ▲3.678 | ▼-1.316 |
| Price To Operating Cash Flow Ratio | 18.664 | ▲1.675 | ▼-2.287 |
| Debt To Assets Ratio | 0.260 | ▼-0.029 | ▼-0.025 |
| Debt To Equity Ratio | 0.610 | ▼-0.128 | ▼-0.119 |
| Debt To Capital Ratio | 0.379 | ▼-0.046 | ▼-0.042 |
| Long Term Debt To Capital Ratio | 0.337 | ▼-0.057 | ▼-0.042 |
| Financial Leverage Ratio | 2.344 | ▼-0.207 | ▼-0.209 |
| Working Capital Turnover Ratio | -29.870 | ▼-15.502 | ▲330.596 |
| Operating Cash Flow Ratio | 0.476 | ▲0.050 | ▲0.101 |
| Operating Cash Flow Sales Ratio | 0.248 | ▲0.029 | ▲0.033 |
| Free Cash Flow Operating Cash Flow Ratio | 0.595 | ▼-0.018 | ▼-0.048 |
| Debt Service Coverage Ratio | 3.620 | ▲0.027 | ▲1.118 |
| Interest Coverage Ratio | 8.113 | ▲2.166 | ▲3.539 |
| Short Term Operating Cash Flow Coverage Ratio | 4.576 | ▼-0.925 | ▲1.021 |
| Operating Cash Flow Coverage Ratio | 0.491 | ▲0.097 | ▲0.135 |
| Capital Expenditure Coverage Ratio | 2.468 | ▼-0.118 | ▼-0.395 |
| Dividend Paid And Capex Coverage Ratio | 1.340 | ▲0.053 | ▲0.084 |
| Dividend Payout Ratio | 0.485 | ▼-0.173 | ▼-7.045 |
| Enterprise Value Multiple | 14.928 | ▲0.281 | ▼-6.944 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $272.02B | $201.50B | $207.45B | $210.87B | $164.28B | |
| Enterprise value | $296.02B | $226.13B | $230.23B | $233.85B | $188.63B | |
| EV / Sales | 5.04x | 4.18x | 5.03x | 5.27x | 5.04x | |
| EV / Op. cash flow | 20.31x | 19.07x | 22.25x | 23.84x | 31.63x | |
| EV / Free cash flow | 34.14x | 31.08x | 35.06x | 32.31x | 50.13x | |
| EV / EBITDA | 14.93x | 14.65x | 17.15x | 25.74x | 36.89x | |
| Net debt / EBITDA | 1.21x | 1.59x | 1.70x | 2.53x | 4.76x | |
| Current ratio | 0.94x | 0.93x | 0.82x | 0.86x | 1.16x | |
| Income quality | 1.43x | 1.36x | 1.50x | 3.92x | -22.50x | |
| Graham number | $68 | $52 | $46 | $34 | $7 | |
| Graham net-net | -$29 | -$30 | -$30 | -$28 | -$35 | |
| Tax burden | 82.7% | 80.9% | 86.3% | 131.5% | -42.3% | |
| Interest burden | 88.0% | 83.8% | 81.3% | 65.3% | -26.2% | |
| Working capital | -$1.89B | -$2.04B | -$5.49B | -$3.70B | $3.65B | |
| Invested capital | $71.90B | $67.81B | $63.15B | $64.88B | $76.20B | |
| Return on assets | 9.0% | 6.8% | 5.9% | 3.4% | 0.1% | |
| Operating ROA | 12.6% | 9.8% | 8.3% | 3.7% | 1.2% | |
| Return on tangible assets | 18.7% | 15.3% | 13.9% | 8.8% | 0.3% | |
| Return on equity | 21.1% | 17.2% | 15.2% | 8.9% | 0.3% | |
| Return on invested capital | 13.0% | 10.3% | 9.3% | 5.0% | -0.5% | |
| Return on capital employed | 16.5% | 13.1% | 11.6% | 5.4% | 1.3% | |
| Earnings yield | 3.8% | 3.5% | 2.9% | 1.6% | 0.1% | |
| Free cash flow yield | 3.2% | 3.6% | 3.2% | 3.4% | 2.3% | |
| Capex / Op. cash flow | 40.5% | 38.7% | 36.5% | 26.2% | 36.9% | |
| Capex / Depreciation | 103.0% | 90.5% | 76.6% | 46.9% | 33.7% | |
| Capex / Sales | 10.1% | 8.5% | 8.2% | 5.8% | 5.9% | |
| SG&A / Sales | 34.9% | 37.4% | 39.8% | 40.5% | 41.7% | |
| R&D / Sales | 24.2% | 25.1% | 23.9% | 22.0% | 26.0% | |
| Stock comp / Sales | 0.0% | 0.0% | 1.3% | 1.4% | 1.6% | |
| Intangibles / Total assets | 51.8% | 55.9% | 57.5% | 61.3% | 59.2% | |
| Days sales outstanding | 94d | 76d | 67d | 76d | 79d | |
| Days payables outstanding | 868d | 130d | 144d | 75d | 83d | |
| Operating cycle | 319d | 265d | 306d | 214d | 343d | |
| Cash conversion cycle | -548d | 135d | 162d | 139d | 260d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+35.0%EV / Sales ▲+20.5%EV / EBITDA ▲+1.9%EV / Op. cash flow ▲+1.245Earnings yield ▲+0.003Graham number ▲+16.529
Profitability
Return on equity ▲+0.038Return on assets ▲+0.022Return on invested capital ▲+0.027Return on capital employed ▲+0.033Operating ROA ▲+0.029Income quality ▲+0.061Tax burden ▲+0.017
Efficiency
Days sales outstanding ▲+18.471Days payables outstanding ▲+737.623Operating cycle ▲+54.456Cash conversion cycle ▼-683.167Capex / Sales ▲+0.016R&D / Sales ▼-0.009
Balance-sheet strength
Current ratio ▲+0.011Net debt / EBITDA ▼-0.385Working capital ▲+145000000.000Invested capital ▲+4087000000.000Intangibles / Total assets ▼-0.041
Change over 5 years
Valuation
Market cap ▲+65.6%EV / Sales -0.0%EV / EBITDA ▼-59.5%EV / Op. cash flow ▼-11.324Earnings yield ▲+0.037Graham number ▲+61.351
Profitability
Return on equity ▲+0.208Return on assets ▲+0.089Return on invested capital ▲+0.136Return on capital employed ▲+0.152Operating ROA ▲+0.114Income quality ▲+23.927Tax burden ▲+1.250
Efficiency
Days sales outstanding ▲+14.982Days payables outstanding ▲+784.910Operating cycle ▼-23.568Cash conversion cycle ▼-808.478Capex / Sales ▲+0.042R&D / Sales ▼-0.018
Balance-sheet strength
Current ratio ▼-0.223Net debt / EBITDA ▼-3.554Working capital ▼-5544000000.000Invested capital ▼-4308000000.000Intangibles / Total assets ▼-0.074
Employee count
Peer market caps
Recent news
- 2026-10-05 AstraZeneca CEO says Summit drug could drive next generation of cancer combinations after $2 billion investment AstraZeneca CEO Pascal Soriot told CNBC that Summit Therapeutics'' lead drug could help power next-generation cancer combinations that could be the "future of cancer care." Soriot spoke exclusively with CNBC from the site of AstraZeneca''s new more than $1 billion research and development facility in Kendall Square in Cambridge, Massachusetts.
- 2026-10-05 Park National Corp OH Purchases 67,214 Shares of Astrazeneca Plc $AZN Park National Corp OH purchased a new position in Astrazeneca Plc (NYSE: AZN) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 67,214 shares of the company''s stock, valued at approximately $10,853,000. Other hedge funds also recently bought and sold shares of
- 2026-10-05 AstraZeneca opens new global strategic R&D center in Kendall Square, Cambridge, Massachusetts WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced the opening of its newest global strategic research and development (R&D) center, in Kendall Square, Cambridge, Massachusetts. The new state-of-the-art facility builds on the Company''s existing presence in Cambridge and Boston and places its scientists at the heart of one of the world''s most innovative life sciences ecosystems. Together with its site for genomic medicine at 100 Binney Street, The AstraZeneca R&D Center Kenda.
- 2026-10-05 SMMT Inks Deal With AZN-Daiichi to Study Ivonescimab + Datroway Combos Summit is teaming up with AstraZeneca and Daiichi to test ivonescimab with Datroway across breast and lung cancers, broadening its potential.
- 2026-10-05 AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the successful closing of AstraZeneca''s (LSE/STO/NYSE: AZN) strategic equity investment in Summit. The equity investment will support continued acceleration of the development of ivonescimab, a novel, potential first-in-class investigational PD-1 / VEGF bispecific antibody. Pursuant to the terms of the Securities Purchase Agreement entered into by Summit and AstraZeneca, AstraZeneca purchased an aggregate of approxi.
- 2026-10-05 Biofrontera (NASDAQ:BFRI) & Astrazeneca (NYSE:AZN) Critical Contrast Astrazeneca (NYSE: AZN - Get Free Report) and Biofrontera (NASDAQ: BFRI - Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings. Institutional and Insider Ownership 20.4% of Astrazeneca shares are owned
- 2026-10-02 AstraZeneca Stocks Moves Lower as Datroway Combination Enters Phase 3 AstraZeneca (AZN), the oncology and biopharmaceutical company, expanded its cancer-drug collaboration with Summit Therapeutics as U.S. shares edge a bit lower a
- 2026-10-02 AstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination AstraZeneca and Daiichi Sankyo have entered into a clinical collaboration with Summit Therapeutics to test their cancer drug, Datroway, in combination with Summit''s ivonescimab across multiple tumour types, including lung and breast cancers.
- 2026-10-02 Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (Nasdaq: SMMT) today announced a clinical trial collaboration agreement with Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) to evaluate ivonescimab, a novel, potential first-in-class investigational PD-1 / VEGF bispecific antibody, in combination with Datroway® (datopotamab deruxtecan), a TROP2-directed antibody drug conjugate (ADC), across multiple solid tumor settings, intending to include breast and lung cancer. The companies i.
- 2026-10-02 Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types TOKYO--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) have entered into a clinical trial collaboration agreement with Summit Therapeutics Inc. (Nasdaq: SMMT) to evaluate Datroway® (datopotamab deruxtecan) in combination with ivonescimab across multiple tumor types including lung and breast cancers. The companies intend to begin with a phase 3 trial in first-line triple negative breast cancer (TNBC). Datroway is a specifically engineered TROP2 directed DXd antibo.